AB1602 CROSS COUNTRY DIFFERENCES IN B/TSDMARD PRESCRIPTION BEHAVIOR: ASSOCIATIONS BETWEEN SOCIOECONOMICS, REAL WORLD B/TSDMARD USE AND DISEASE OUTCOMES

Background The development of biologic and targeted synthetic (b/ts)DMARDs contributed to improved treatment outcomes in rheumatoid arthritis (RA). However, high medications costs may limit their use. Previously we showed that countries with a lower socioeconomic status (SES), b/tsDMARDs were prescribed fewer patients than higher SES. In this study take more detailed look at b/tsDMARD prescription behavior between countries. Objectives To explore cross-country relationships Gross Domestic Product (GDP) per capita, specific indicators use disease RA. Methods This multinational, observational included had ≥100 using b/tsDMARDs, available follow up, one 2 registries: METEOR, an international registry capturing daily clinical practice data diagnosis RA, JAK-POT, investigator-initiated collaboration national registries aiming evaluate aspects On per-country basis, mean DAS28 was calculated from the last follow-up visit patient. usage determined as time start therapy since date diagnosis, number tried patient duration therapy. calculate first country JAK-POT registry, only bionaïve included. Possible associations GDP capita country-level tested univariable linear regression models. Regression coefficients (β) are interpreted numerical increase outcome 1 point predictor. Results Data 25,832 living 17 different varying behavior. ranged 6505 (India) 93350 Intl$ (Ireland). Time 0.5 (Austria) 11.1 (Finland) years. Mean 1.0 (Turkey) 2.4 (Switzerland). Duration 0.9 5.5 (Portugal) years (Figure 1). Baseline 3.7 6.1, but not related any use: β 0.08 (95% CI -0.7; 0.9), 0.06 -0.03; 0.2), 0.1 -0.3; 0.5). No statistically significant observed 1A, 0.09 95% (fig 1B, 0.07 -0.02; 0.2) or 1C, None significantly end up: 0.02 -0.05; 0.1), -0.03 -0.2; 0.1) -0.6; 0.6). Conclusion activity across worldwide. Overall, differences behaviour did appear be welfare and, no association level. seems indicate once b/tsDMARD, has less impact on REFERENCES: NIL. Acknowledgements: Disclosure Interests Isabell Nevins: declared, Delphine Courvoisier: Axel Finckh Speakers bureau: AbbVie, BMS, Pfizer, Eli-Lilly, Sandroz, Consultant of: Novartis, MSD, Lilly, Grant/research support from: Galapagos, Ruth Fritsch-Stork: Dan Nordström: Ana Maria Rodrigues: ȘTEFAN CRISTIAN DINESCU: Álvaro García Martos: Mert Oztas: Ziga Rotar: Karen Solomon-Escoto: Arvind Chopra: David Vega-Morales: Petronella DM de Buck: Denis Choquette: Richard Conway Janssen, Roche, Sanofi, Fresenius Kabi, Viatris, Celltrion, Nordic Pharma, Abbvie, Florenzo Iannone: Cornelia Allaart: Thomas Huizinga: Kim Lauper: Sytske Anne Bergstra ASPIRE grant Pfizer.